FDA has approved Ofev, first treatment for patients with interstitial lung disease associated with systemic sclerosis or scleroderma
The FDA ( U.S. Food and Drug Administration ) has approved Ofev ( Nintedanib ) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.
It is the first FDA-approved treatment for this rare lung condition.
Scleroderma is a rare disease that causes tissue throughout the body, including the lungs and other organs, to thicken and scar.
Interstitial lung disease or ILD is a condition affecting the interstitium, which is part of the lung’s structure, and is one of the most common disease manifestations of scleroderma.
SSc-ILD is a progressive lung disease in which lung function declines over time, and it can be debilitating and life-threatening.
Interstitial lung disease is the leading cause of death among people with scleroderma, typically resulting from a loss of pulmonary function that occurs when the lungs cannot supply enough oxygen to the heart.
Approximately 100,000 individuals in the United States have scleroderma, and approximately half of scleroderma patients have SSc-ILD.
The effectiveness of Ofev to treat SSc-ILD was studied in a randomized, double-blind, placebo-controlled trial of 576 patients ages 20-79 with the disease.
Patients received treatment for 52 weeks, with some patients treated up to 100 weeks.
The primary test for efficacy measured the forced vital capacity, or FVC, which is a measure of lung function, defined as the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
Those who took Ofev had less lung function decline compared to those on placebo.
The overall safety profile observed in the Ofev treatment group was consistent with the known safety profile of the therapy.
The most frequent serious adverse event reported in patients treated with Ofev was pneumonia ( 2.8% Ofev versus 0.3% placebo ).
Adverse reactions leading to permanent dose reductions were reported in 34% of Ofev-treated patients compared to 4% of placebo-treated patients.
Diarrhea was the most frequent adverse reaction that led to permanent dose reduction in patients treated with Ofev.
The prescribing information for Ofev includes warnings for patients with moderate or severe hepatic impairment, those with elevated liver enzymes and drug-induced liver injury and patients with gastrointestinal disorders.
Ofev may also cause embryo-fetal toxicity that can result in fetal harm, arterial thromboembolic events, bleeding and gastrointestinal perforation.
P-gp and CYP3A4 inhibitors may increase Nintedanib exposure, and patients taking these inhibitors should be closely monitored for tolerability of Ofev.
Common side effects noted with Ofev include diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight loss and hypertension.
Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis ( IPF ), which is another interstitial lung condition. ( Xagena )
Source: FDA, 2019
FDA has approved Emgality, the first treatment for episodic cluster headache that reduces the frequency of attacks
The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for...
The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer. Approval was...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Direct-acting antivirals reduce risk of premature mortality and liver cancer for patients with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...
Standard methods to detect NTRK fusions in daily practice and clinical research: ESMO recommendations
NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most...